A new medical study suggests that children whose leukaemia returns may live longer and have a better quality of life with a gentler treatment approach. The research was led by Dr David O’Connor, a specialist at University College London, together with a wider team of clinicians.
The study shows that using less intensive chemotherapy can improve safety for young patients. It also removes deaths linked directly to the early phase of treatment. The research study UKALL Rel2020 is published in the journal Leukemia.
In this approach, children first receive a lower dose of chemotherapy. After that, they are given a targeted immunotherapy drug called blinatumomab. This drug helps the immune system recognise and destroy leukaemia cells more effectively.
The study involved 188 patients aged between one and 24 years. They were treated across 25 hospitals in the United Kingdom. The treatment period ran from 2020 to 2024. About 92 per cent of patients went into remission after receiving the new treatment plan. Around 82 percent survived for at least three years. This result is similar to outcomes seen with stronger, more traditional treatment methods.
No deaths were recorded during the early stage of treatment. Doctors say this is a major improvement in safety for children with relapsed acute lymphoblastic leukaemia. Acute lymphoblastic leukaemia is the most common childhood cancer in the UK. Around 400 children are diagnosed each year. Many children recover after first treatment, but relapse remains a serious challenge.
Dr O’Connor said that earlier treatment methods often involved high risks. He explained that the new approach lowers those risks while still being effective against cancer. One child involved in the study was Romyn Winters. Her parents first became concerned when she started having trouble walking and became very weak and tired.
In 2018, tests confirmed she had ALL. She began treatment in hospital soon after her diagnosis. Her first chemotherapy helped, but it caused strong side effects. Sadly, her cancer returned around 18 months later.
At that point, her family had to choose between a bone marrow transplant or a newer treatment using blinatumomab combined with lighter chemotherapy. They chose blinatumomab because it seemed less harsh and offered more flexibility if further treatment was needed.
Romyn experienced only mild side effects at first. Her condition improved rapidly. She continued treatment at home using a small infusion pump. The pump was carried in a backpack. Soon, her strength returned. She went back to playing. She resumed normal childhood activities.
After completing treatment, she recovered well and had her medical devices removed. She later enjoyed everyday life again, including learning to swim quickly after finishing therapy. Her family also took her on a holiday, where she continued to recover.
Researchers noted that this trial was delivered as part of routine NHS care. This made the results more realistic for everyday patients in real hospital settings. Traditional high-dose chemotherapy can cause strong side effects. These include infections, tiredness, and damage to healthy cells. Blinatumomab works in a different way. It connects immune T-cells directly to leukaemia cells. This helps the body attack the cancer more precisely. Because it is targeted, it causes less harm to healthy tissue than standard chemotherapy.
Doctors say using this method within NHS hospitals shows it can work safely in everyday clinical settings. Researchers believe the results could lead to changes in how relapsed childhood leukaemia is treated worldwide. Families also reported that children spent less time in hospital and had better daily energy levels during recovery.
This made the treatment easier to manage for both patients and parents. Scientists say the study offers strong evidence that gentler, targeted therapies can replace more aggressive chemotherapy without reducing the chances of survival for many child patients safely.
